Safety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection.
Eleven pediatric patients, aged 1 to 10 years and with symptomatic human immunodeficiency virus infection, were treated with 6 or 10 mg of oral ribavirin per kg of body weight daily for 60 days. Safety and pharmacokinetic parameters were monitored; five children had comprehensive pharmacokinetic evaluations. The children tolerated the drug well, and treatment was not associated with any clinically significant adverse effects. Peak concentrations in plasma of 2.5 and 3.0 microM were reached at 90 min after single oral doses of 6 and 10 mg/kg, respectively. The mean systemic availability of oral ribavirin was 42.3%. After 60 days of ribavirin administration, mean trough concentrations in plasma of 2.6 and 4.1 microM were obtained. Ribavirin penetrated well into the cerebrospinal fluid, achieving 70% of the concentration in plasma at steady state.
Connor
E
E
Department of Pediatrics, Children's Hospital of New Jersey, Newark.
Morrison
S
S
Lane
J
J
Oleske
J
J
Sonke
R L
RL
Connor
J
J
D000163:Acquired Immunodeficiency Syndrome / Q000097:blood / Q000188:drug therapy* / Q000382:microbiology; D000284:Administration, Oral; D002648:Child; D002675:Child, Preschool; D004334:Drug Administration Schedule; D004361:Drug Tolerance; D005260:Female; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D007223:Infant; D008297:Male; D012254:Ribavirin / Q000009:adverse effects* / Q000493:pharmacokinetics* / Q000627:therapeutic use
D012254:Ribavirin